– USA, CA – Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next-generation cancer and infectious disease immunotherapies, today announced the appointments of Dr. Naiyer Rizvi, MD. and Dr. Shefali Agarwal, M.D., MPH. to the Board of Directors.
Dr. Naiyer Rizvi is the newly appointed chief medical officer at Synthekine, a private biotechnology company, and until recently Price Family Professor of Medicine, director of Thoracic Oncology and co-director of Cancer Immunotherapy at Columbia University Medical Center, and Dr. Shefali Agarwal, M.D., M.P.H., is EVP and chief medical and development officer at Epizyme, Inc.
Concurrently, Dr. Tom Woiwode, managing director at Versant Ventures, and Nicholas Simon, senior managing director at Blackstone Life Sciences, have stepped down from the Board.
“I am thrilled to welcome Naiyer and Shefali to our Board of Directors,” said Dr. Andrew Allen. “Naiyer is a co-founder of Gritstone, member of our scientific advisory board, and a medical oncologist renowned for his expertise in immuno-oncology. Shefali is a physician who has spent over a decade leading the clinical development of breakthrough medicines, including PARP inhibitors and the only-in-class EZH2 inhibitor, tazemetostat, in her current role at Epizyme. She also sits on the board at Fate Therapeutics and has a front-row seat in the development of novel cell therapies for cancer. These additions to our Board reflect our commitment to pursuing science-based, operationally optimized programs to address unmet need with our innovative technologies, therapeutics, and prophylactic vaccines.”
Dr. Allen added, “Additionally, on behalf of the entire company, I would like to sincerely thank Tom and Nick for their years of dedication and service to the Board, starting in 2015 when they drove our Series A financing.”
About Dr. Naiyer Rizvi
Dr. Naiyer A. Rizvi is chief medical officer at Synthekine, a private, engineered, and synthetic cytokine therapeutics company. Until May 2021, he was the Price Family Professor of Medicine, Director of Thoracic Oncology, and Co-Director of Cancer Immunotherapy at Columbia University Medical Center He received an M.D. at the University of Manitoba in Winnipeg, Canada, and completed a fellowship in medical oncology at Beth Israel Hospital/Harvard Medical School. Dr. Rizvi was an attending physician in thoracic oncology and early drug development at Memorial Sloan Kettering Cancer Center where his translational research focused on immune-checkpoint blockade drug development. His research studies were integral to the approval of immune-checkpoint blockade in lung cancer, including approval of nivolumab in squamous lung cancer and pembrolizumab in non-small cell lung cancer. He authored a publication in Science of data from a landmark trial — the first study to demonstrate a statistically significant correlation between mutations and neoantigens with durable benefit to the immune-checkpoint blockade. Dr. Rizvi is a co-founder of Gritstone.
About Shefali Agarwal
Dr. Shefali Agarwal is EVP and chief medical and development officer at Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies. Before joining Epizyme in 2018, she held leadership positions across medical research, clinical development, clinical operations, and medical affairs. Dr. Agarwal most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA in ovarian cancer. Dr. Agarwal has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer.
In addition to receiving her medical degree, Dr. Agarwal holds a master’s of public health and a master’s of science in business. She currently sits on the Board of Directors of Fate Therapeutics.
About Gritstone bio, Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as a tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health, the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.
For more information: https://gritstonebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.